Cenix BioScience and Metanomics Health Sign Research Agreement

Cenix BioScience GmbH, a leading preclinical contract research provider and technology developer specialized in genome-scale gene modulation studies and high throughput, high content pharmacology, today announced that it has signed a research framework agreement with Metanomics Health GmbH, a BASF Group company, focused on comprehensive metabolite profiling services and the development of metabolomic biomarkers.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Dresden, Germany (PRWEB) August 26, 2014

Cenix BioScience GmbH, a leading preclinical contract research provider and technology developer specialized in genome-scale gene modulation studies and high throughput, high content pharmacology, today announced that it has signed a research framework agreement with Metanomics Health GmbH, a BASF Group company, focused on comprehensive metabolite profiling services and the development of metabolomic biomarkers.

As the agreement’s first work assignment, Metanomics Health has commissioned Cenix to undertake a target validation project for an undisclosed disease indication. Under the jointly developed work plan, Cenix will leverage its longstanding industry-leading expertise in high content screening, utilizing the Definiens XD image analysis platform, for comprehensive functional characterization of target genes designated by Metanomics Health.

“We foresee very strong synergies between our own capabilities and the exciting approach taken by Metanomics Health towards biomarker discovery and validation,” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “We appreciate and value the trust of our colleagues at Metanomics Health and look forward to advancing their programs."

Financial terms were not disclosed.

About Cenix BioScience
With operations in Germany and the U.S., Cenix BioScience conducts contract research and develops new reagent technologies focused on a wide array of preclinical cell-based and in vivo applications including RNAi-based gene silencing, miRNA modulation, compound testing, advanced genomics analyses and high content screening to accelerate drug discovery and development. Now in its 15th year, Cenix has established unrivaled scientific and commercial track records in this field, successfully advancing therapeutic programs for numerous industry and academic partners in a broad range of disease fields. This success, illustrated by a high rate of repeat business from top clients and an ever-growing list of new clients, is driven by the consistent application of industrial best practices through highly customized, multi-staged projects. Their careful design yield maximal strategic value and accountability, with minimized risk and full data transparency. More information: http://www.cenix.com.

About Metanomics Health
Metanomics Health GmbH, a BASF Group company, was founded in 2003 and is a leader in robust, non-targeted and targeted comprehensive metabolite profiling services (metabolomics) to healthcare customers. Serving pharma, nutrition and diagnostics companies, as well as academic partners, Metanomics Health’ state-of-the-art biomedical data interpretation, combined with innovative bioinformatics and data mining systems, enables discovery and validation of both simple and complex metabolomic biomarkers. Metanomics Health delivers novel biomarkers of disease and drug efficacy, increased mechanistic understanding of drug action and adverse effects, as well as insights into underlying pathways to its partners, thereby providing actionable results for healthcare research and development programs. More information: http://www.metanomics-health.de.

Contact
Dr. Christoph Sachse
Director Cell-based Services
Cenix BioScience GmbH
E: info(at)cenix(dot)com
W: http://www.cenix.com

Cenix and the Cenix BioScience logo are registered trademarks owned by Cenix BioScience GmbH. Definiens XD and Definiens are registered trademarks owned by Definiens AG.


Contact

Attachments